Get Free Demat Account*
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
By Dalal Street Investment Journal (DSIJ)
Tatva Chintan Pharma Chem shares hit a 20% upper circuit after the company reported record quarterly revenue and profit. Strong earnings, a ₹200 crore greenfield expansion at Dahej and a sharp jump in trading volumes pushed the stock to a fresh 52-week high, extending its strong gains in 2026.
Tatva Chintan Pharma Chem attracted attention after posting strong Q1 results. The stock hit its 20% upper circuit mark in the early trade on Monday and now trades at its 52-week high.
Trading volumes also jumped during the day. Around 2.57 million shares changed hands during the session, far above the stock's average 30-day volume of 134.71 thousand shares.
The company reported strong numbers as a result of healthy demand across its specialty chemical portfolio. Consolidated net profit rose 140.3% year-on-year to ₹15.98 crore, compared with ₹6.65 crore in the same quarter last year. On a sequential basis, profit increased 54.84% from ₹10.32 crore.
Revenue also posted healthy growth. Consolidated revenue climbed 42.95% year-on-year to ₹167.06 crore, while it increased 24.54% over the previous quarter from ₹134.14 crore. Operating performance improved as well. EBITDA stood at ₹32.30 crore, up 86.71% from a year ago. Compared with the March quarter, EBITDA grew 14.95% from ₹28.10 crore.
Alongside the quarterly results, the board approved a ₹200 crore investment for the proposed Dahej-III facility. The expansion will add 344 KL of reactor capacity and is aimed at meeting the expected rise in demand for specialty chemicals over the coming years.
Following the company's June quarter results announced after market hours on Friday, the Tatva Chintan share price opened in the green on Monday, July 20, 2026. The stock opened at ₹1,525.00, up 6.79% from its previous close of ₹1,428.10.
Buying momentum increased during the session, and the stock reached its 20% upper circuit limit. It touched an intraday high of ₹1,713.70. The stock's past performance has also been strong. It is up over 26.78% in 2026 and has gained more than 67% in the past year.
Tatva Chintan Pharma Chem is an integrated specialty chemical company. The company was established in 1996 and holds a presence across the specialty chemicals value chain. Its manufacturing facilities are located at Ankleshwar and Dahej SEZ in Gujarat. As of March 31, 2026, the company had a combined installed reactor capacity of 791 KL and 39 assembly lines.
Source: Dalal Street Investment Journal (DSIJ), NSE, BSE
SEBI Registered Research Analyst (INH000006396).
Founded in 1986, Dalal Street Investment Journal (DSIJ) brings decades of experience in India’s equity markets. DSIJ's research combines fundamental analysis with price action, guided by disciplined risk management and capital preservation. They follow a structured, data-driven approach designed to help investors and traders make informed decisions beyond short-term market noise.
Disclaimer :
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Scan the QR to download the Bajaj Broking App for effortless investing and trading